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Treatment of Gestational Diabetes
Ahmed Mohamed Maged
Abstract
Management of gestational diabetes mellitus (GDM) should consider both 
the maternal, fetal, and neonatal effects of the disease, line of treatment, and 
physiological changes during pregnancy. Women with GDM are classified into 
two categories according to their fasting blood glucose levels. Dietary control is 
mandatory in both classes, and the addition of pharmacological agents in those with 
fasting and 2-h postprandial plasma glucose levels <95 and 120 mg/dL is controver-
sial (American College of Obstetricians and Gynecologists, 2013). Individualization 
of the diet in GDM according to women weight and height is recommended by the 
American Diabetes Association (ADA), and restriction of carbohydrate to a level 
that maintains normal glucose level is mandatory with individualization of the 
caloric intake according to women BMI and weight gain during pregnancy.
Keywords: gestational diabetes, management, diabetic diet, insulin, exercise,  
oral hypoglycemic
1. Introduction
The main aim of treatment of gestational diabetes is to prevent fetal, maternal, and 
neonatal complications. A randomized controlled trial which involved 1000 women with 
GDM showed that treatment of GDM is associated with the reduction of all neonatal 
complications, namely, birth injuries, shoulder dystocia, and perinatal morbidity and 
mortality. Treatment also reduced the rate of development of preeclampsia from 18 to 
12% and the rate of large for gestational age (LGA) from 22 to 13% [1]. Even in women 
with mild GDM, treatment reduced the rate of LGA, the mass of neonatal fat, shoulder 
dystocia, cesarean section, and hypertensive disorders associating pregnancy [2, 3].
Improving the pregnancy outcome in women with GDM can be achieved 
through maintenance of fasting blood sugar levels <95 mg/dl (5.3 mmol/L), 1-h 
postprandial blood sugar <140 mg/dl (7.8 mmol/L), and 2-h postprandial blood 
sugar <120 mg/dl as recommended by both the American College of Obstetricians 
and Gynecologists (ACOG) and American Diabetes Association [4].
The treatment of GDM starts with dietary modifications along with particular 
nutritional approaches [5–7] combined with exercise [8, 9]. If this combination 
failed to maintain the needed glucose levels, pharmacological treatment starts, 
regardless of the lines used for treatment, proper monitoring of maternal health, 
fetal condition, and blood sugar levels.
1.1 Dietary modifications
Dietary counseling should be individualized according to women weight and 
height [10] through a registered dietitian [11].
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JSOG committee on nutrient and metabolism problems described a caloric 
intake of 25–30 kcal/kg (+150 Kcal for the first half and + 350 kcal for the second 
half of pregnancy) [12].
The Ministry of Health and Welfare recommended a caloric intake of 
25–30 kcal/kg (+ 50,250 and 450 kcal for the first, second, and third trimester, 
respectively) [13].
The ideal diet components are not yet determined. However excessive weight 
gain with postprandial hyperglycemia is commonly associated with diet that 
included 50–60% of carbohydrate. ACOG recommended the limitation of carbohy-
drate to 33–40% of the required calories and the remaining 60% to be gained from 
proteins (20%) and fats (40%) [4].
The complex form of carbohydrates is preferable over simple ones as they are 
absorbed slower without producing significant hyperglycemia. Complex carbohy-
drates also decrease insulin resistance [6].
If the routine three meals daily failed to achieve the target blood sugar, each 
meal should be divided in 2:1 or 1:1 ratio to eat 4–6 meals per day [14].
The ADA recommended “MyPlate” as a healthy guide for each meal which 
consists of 25% protein, 25% starch, and 50% non-starchy foods as vegetables espe-
cially steamed ones. Creating MyPlate is a simple and effective method allowing 
proper control of the blood glucose levels and losing weight (http://www.diabetes.
org/food-and-fitness/food/planning-meals/create-your-plate/).
Some foods to be avoided include highly processed foods as white bread, fast 
foods, alcohol, baked products as muffins and cakes, sugary drinks, candy, and high 
starch foods as white rice and white potatoes.
2. Exercise
Although there are many randomized studies done to evaluate the effects of 
physical exercise and lifestyle modifications in adults with diabetes, only few ones 
evaluated these effects in pregnant women with GDM. These studies proved that 
exercise improves the blood glucose [8, 15–18]. These beneficial effects may occur 
as a result of the increase of lean muscle mass with subsequent increase in insulin 
sensitivity. So a moderate exercise program is highly recommended for women 
with GDM [11]. A moderate intensity aerobic exercise for at least 150 minutes 
weekly [19] or simple exercise as walking after each meal for 10–15 minutes [20] is 
recommended.
The Finnish GDM prevention trial (RADIEL)—a multicenter randomized 
controlled study—evaluated the efficacy of combined dietary and physical activity 
modifications in prevention of GDM and obesity-related perinatal complications 
[21]. Counseling was achieved through three visits to the study nurse at 13, 23, 
and 35 weeks of pregnancy. Dietary modification was done according to Nordic 
Nutrition Recommendations encouraging the intake of vegetables, fruits and ber-
ries, high-fiber whole-grain products, low-fat dairy products, vegetable fats high 
in unsaturated fatty acids, and fish and low-fat meat products with lower intake 
of sugar- and saturated fatty acid-rich foods. [22]. Physical moderate exercise for 
150 minutes at least per week is recommended [23]. They found that these modifica-
tions had no effects on either the incidence of GDM or perinatal complications [24].
2.1 Pharmacologic treatment
Pharmacologic treatment is indicated when dietary management and exercise 
failed to achieve the target glucose levels.
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Basically, insulin is the standard treatment for GDM [11]. Insulin has the 
advantage of non-crossing of the placenta. It is given according to the timing of the 
occurrence of hyperglycemia. If hyperglycemia is present throughout the day both 
in the fasting and postprandial state, a divided dose of combination of either long 
or intermediate acting insulin with the short acting one is recommended. The typi-
cal total starting dose is 0.7–1 unit/ kg of body weight. If hyperglycemia is detected 
only at a specific times, focusing the insulin dose at that specific time of hyperglyce-
mia is done, e.g., high fasting blood sugar is treated using a nighttime intermediate-
acting insulin, while elevated post-breakfast blood sugar is treated by short-acting 
insulin before breakfast. The maintenance dose is then adjusted according to the 
monitored blood glucose [4].
The insulin analogs as insulin aspart and lispro are preferred over the regular 
insulin as a short-acting type. They do not cross the placenta, and their main advan-
tage is their faster onset of action allowing the women to receive their injection at 
the time of the meal not 10–15 minutes before it as needed in the regular type. This 
advantage provides better control of the glucose level, and less attacks of hypogly-
cemia resulted from timing error [25, 26]. Intermediate- and long-acting insulin 
include the basic isophane insulin (NPH) and recent insulin glargine and detemir 
(Table 1) [27–29].
2.1.1 Oral antidiabetic medications
Historically oral hypoglycemics should be avoided as early agents cross the 
placenta, resulting in fetal hyperinsulinemia with subsequent macrosomia and 
congenital malformations (most commonly in the ear) and severe neonatal hypo-
glycemia. Now their use in GDM is increasing despite them not approved by the US 
Food and Drug Administration [31] and the recommendation of ADA that insulin 
is the first-line therapy for GDM [11] as these products have advantages as ease of 
tablet intake, ease of storage, and safe needle disposal.
Oral antidiabetic medications include biguanides, sulfonylurea, acarbose, Guar 
gum, and thiazolidinedione.
Metformin is a biguanide that decreases intestinal glucose absorption and 
hepatic gluconeogenesis and increases peripheral glucose uptake. Historically, it was 
given to women used in pregestational diabetic women and women with polycystic 
ovary syndrome who suffer from infertility. In the latter group, it was continued 
until completion of the first trimester, despite the limited evidence of its ability to 
improve pregnancy outcome [32].
Type Onset 
(min)
Peak  
(h)
Duration 
(h)
Insulin lispro 1–15 1–2 4–5
Insulin aspart 1–15 1–2 4–5
Regular insulin 30–60 2–4 6–8
Isophane insulin suspension (NPH) 60–180 5–7 13–18
Insulin glargine 60–120 No peak 24
Insulin detemir 60–180 Minimal at 8–10 18–26
Modified from Gabbe and Graves [30].
Table 1. 
Describes the onset, peak, and duration of action of the commonly used insulins.
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Although metformin can cross the placenta, its long-term metabolic effects 
on the growing fetus are not known [33]. One study showed the absence of any 
developmental effects till the age of 2 years of life [34].
In a randomized controlled trial, 751 pregnant women having GDM were 
assigned to treatment with insulin or metformin ± insulin. The perinatal outcome 
was similar among the two groups [35].
Another smaller trial showed that women assigned to metformin had lower 
blood glucose, lower maternal weight gain during pregnancy, and lower incidence 
of neonatal hypoglycemia [36].
In a network meta-analysis that included unpublished trials, there was a differ-
ence between insulin and metformin treatments regarding neonatal birth weight, 
hypoglycemia, or mode of delivery [37].
Therefore, women with GDM are carefully counseled about the use of metfor-
min. They should know that it is not superior to insulin, there are no definitive data 
about its long-term effects of the growing fetus, and 26–46% of women on metfor-
min will need to add insulin to replace it or to potentiate its effects for better glucose 
control [35, 36].
Metformin starting dose is usually 500 mg once daily at nighttime for 1 week, 
and then the dose is increased according to the response. The maximum daily dose 
is 2500–3000 mg daily in two–three divided doses.
Contraindications to metformin include impaired kidney function, and serum 
creatinine should be evaluated before the start of treatment.
Side effects of metformin occur in 2.5–45.7% of cases [38], and the commonest 
is GIT upset in the form of abdominal pain and diarrhea. Its use may be associated 
with higher rate of lactic acidosis, preeclampsia, and neonatal jaundice. So the 
drug is instructed to be administered with meals and to increase the needed dose 
gradually.
A systematic review stated that metformin use during pregnancy is safe and 
effective regarding the short-term pregnancy outcomes. There are no solid guide-
lines about the duration of metformin use during pregnancy, so it is based on 
clinical experience on a case-by-case basis [39].
Sulfonylurea used in GDM includes glyburide, tolbutamide, glibenclamide, and 
gliclazide. Chlorpropamide crosses, while glibenclamide does not cross the placenta.
Glyburide augments insulin secretion by pancreas (through binding adenosine 
triphosphate potassium channel receptors of the beta cells) and extrapancreatic tis-
sues. It also increases insulin sensitivity of peripheral tissues. It should not be used 
as a first-line treatment as most studies showed inferior results when compared to 
insulin or metformin [31].
The dose of glyburide is 2.5–20 mg per day in divided doses. The maximum dose 
is 30 mg daily [40]. Even with these high doses, 4–16% of patients will need the 
addition of insulin for adequate glycemic control [41–44].
Contraindications include allergy to sulfa, and side effects include mild infre-
quent GIT side effects as nausea, vomiting, and diarrhea.
Although some individual trials showed no difference regarding blood glucose 
control between glyburide and insulin [41–46], meta-analyses reported higher 
incidence of macrosomia, maternal, and neonatal hypoglycemia [35, 36, 47]. Other 
trials found that women used glyburide and had higher incidence of hypertension, 
hyperbilirubinemia, and still birth than those on insulin therapy [31, 42, 48–52].
Other sulfonylurea include Thiazolidinedione as Pioglitazone & Rosiglitazone 
which decrease insulin resistance by reducing RESISTIN hormone released from 
adipose tissue. Their use during pregnancy cannot be recommended as no enough 
reports to support their use.
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A Cochrane meta-analysis evaluated 7381 women with GDM and reported 
similar pregnancy outcomes when insulin therapy is compared with oral anti-
diabetic agents (metformin, glyburide, both, and acarbose) [53]. However these 
oral antidiabetic agents have different safety and efficacy, so pooling all of them 
together against insulin weakens that meta-analysis.
To sum up, the current available data show the absence of short-term hazards, 
but the long-term effects are still unknown. So, the women should be counseled 
about the unknown proven safety of the oral antidiabetic agents and the high rate of 
need for adding insulin before describing it.
ACOG considers insulin as the first-line treatment for GDM and describes oral 
agents (mainly metformin and rarely glyburide) as an alternative in women who 
decline insulin use (for financial issues or non-availability of safe administration) 
after proper consultation.
3. Other medications used in GDM
As there are many evidences that link oxidative stress and development of 
complications of diabetes with pregnancy, the use of antioxidants was suggested 
to improve pregnancy outcome [54]. Oxygen free radicals released during aerobic 
metabolism cause cellular damage [55, 56]. Many authors reported the participation 
of reactive oxygen species in diabetes associated with pregnancy [57, 58].
An interesting randomized controlled trial was conducted that involved 200 
women with GDM who were assigned to receive antioxidant (1 gram L-ascorbic 
acid daily) or placebo. Maged and colleagues found that antioxidants significantly 
decreased the required insulin dose to control blood sugar and oxidative markers 
(glutathione, malondialdehyde, superoxide dismutase). In placental tissue homog-
enate, maternal blood and neonatal blood were significantly different between 
the two groups. In the antioxidant group, the neonatal blood sugar was more 
stable within 2 h of delivery, and the neonatal ICU admission was lower than other 
women. They concluded that the use of antioxidant administration during preg-
nancy in women with GDM reverses the oxidative stresses resulting in the improve-
ment of neonatal outcome [59].
4. Glucose monitoring
Monitoring of glucose control is through blood testing urine analysis for glucose 
and ketone bodies and glycosylated hemoglobin.
The optimal frequency of blood glucose testing in women with GDM is not 
known. However, four evaluations daily seem to be satisfactory (fasting and after 
each meal) [4].
Fasting blood sugar is predictive of neonatal fat mass and subsequent devel-
opment of childhood obesity and diabetes [60], and 1-h postprandial level was 
predictive of better blood sugar control and subsequent development of LGA and 
cesarean delivery [61], so both should be measured. The postprandial measurement 
can be after 1 or 2 h as the peak glucose level occurs almost 90 min after meals [62]. 
Measurement neither at 1 h nor at 2 h is superior to the other [63–65].
After stabilization of the blood sugar, individualization of the frequency of 
glucose measurement according to the gestational age, adherence of the patient 
to treatment and the needs of further adjustment is recommended. However the 
minimum is two measurements per day [4].
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Women under self-monitoring of blood glucose daily had significantly lower 
incidence of fetal macrosomia and less weight gain than those under intermittent 
measurement of fasting glucose during semi-weekly antenatal visits [66].
de Veciana and colleagues randomly assigned 66 women with GDM for prepran-
dial or 1-h postprandial measurement of blood sugar. They found that postprandial 
group had better blood glucose control with less macrosomia, cesarean delivery for 
cephalopelvic disproportion, and neonatal hypoglycemia [61].
A review included 10 trials of 538 women (468 and 70 women with type 1 and 
type 2 diabetes). Different glucose monitoring methods were compared without 
clear advantage of one method over the others. Two trials (43 women) comparing 
self-monitoring versus standard care proved no difference for cesarean section 
or glycemic control. One study (100 women) compared self-monitoring versus 
hospitalization and found no clear difference for hypertensive disorders, cesarean 
section, or preterm birth. Another study (61 women) which compared preprandial 
versus postprandial glucose monitoring proved no clear difference regarding 
cesarean section, macrosomia, or glycemic control. Three studies (84 women) 
which compared automated telemedicine monitoring versus conventional 
system found no clear difference for cesarean section and mortality or morbidity. 
CGM was compared to intermittent monitoring in two studies (225 women), and 
there was no difference for preeclampsia and cesarean section and large for gesta-
tional age. One trial (25 women) compared constant CGM versus intermittent 
CGM and found no clear difference between groups for cesarean section, glycemic 
control, or preterm birth [67].
4.1 Glycosylated hemoglobin
Hemoglobin (Hb) A forms about 90% of hemoglobin in adults, and its glyco-
sylation occurs due to irreversible nonenzymatic binding of glucose to N-terminal 
of β chain. Hb A1 is divided into Hb A1 a1, Hb A1 a2, Hb A1 b, and Hb A1 C (the most 
important). The mean plasma glucose over the erythrocyte life span is correlated 
with the degree of glycosylation. Its advantages include that it is a single, non-
fluctuating blood test that reflects the glucose levels over the last 4–8 weeks. So, 
HbA1c is an attractive test that can be added to routine investigations done in the 
first antenatal evaluation as it serves as a diagnostic tool for women with undi-
agnosed diabetes or at risk of its development [68]. If measured during the first 
trimester, it gives an idea about blood glucose control in the periconceptional period 
and during organogenesis. Its main disadvantage is its affection by red blood cell 
turnover [6] which results in the absence of clear recommendations for its use to 
diagnose GDM [69–71]. HbA1C increases also in cases of non-hemolytic anemias 
and chronic renal failure [72]. Women with A1c of 10–12% have up to a 25% risk of 
major malformations.
4.2 Fetal assessment
Like women with pregestational diabetes, women with GDM should follow 
antenatal fetal assessment especially those with poor glycemic control and women 
under medical treatment with insulin or oral antidiabetic agents [73]. It should start 
at 32 weeks of gestational age and earlier in women with GDM associated with other 
factors that may adversely affect fetal outcome as hypertensive disorders [74].
There is no consensus about antepartum fetal monitoring in properly controlled 
women without medical treatment, and if done it usually starts to alter at 32 weeks. 
The specific test used and its frequency are dependent on the regional practice, but 
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amniotic fluid measurement is probably included as polyhydramnios is commonly 
associated with fetal hyperglycemia [4].
At Parkland Hospital, women with GDM are routinely asked to count daily fetal 
kick especially during the third trimester, and women on insulin treatment are 
offered for hospital admission and CTG monitoring three times weekly [74].
5. Obstetrical management
Timing and management of delivery of women with GDM are dependent on 
glycemic control, fetal condition, and associated complications. Women with proper 
glycemic control without associated medical problems are followed up till term [75, 76].
A comparison was done between women with GDM who were subjected to labor 
induction at 38 weeks and those who were followed up till 41 weeks of gestation, 
which revealed similar CS rate and all other outcomes except the higher occur-
rence of neonatal hyperbilirubinemia in one study [77], lower incidence of LGA in 
another study [78], and lower incidence of shoulder dystocia in a third one [79] in 
the induction group. A more recent study found a lower rate of CS in the induction 
group [80]. So women with GDM using medications with proper control of blood 
sugar delivered better during the 39 weeks of gestation [4].
In women with poor control of their blood sugar, timing of delivery is deter-
mined by balancing the risk of prematurity and the ongoing risk of intrauterine 
fetal death. In general earlier delivery in women with good glycemic control is 
recommended [75, 76], but the clear guides for glycemic control and timing of 
delivery are absent [81]. In general delivery between the start of 37 weeks and the 
completion of 38 weeks appears appropriate, while delivery at 34 weeks till the 
completed 36 weeks should be attempted only in women with abnormal fetal well-
being assessment and those with failed hospital control of blood sugar [4].
Ultrasound assessment of fetal size should be done in all women with 
GDM. However only 22% of fetuses diagnosed as LGA by ultrasound had macroso-
mia after birth [82]. To prevent one case of permanent brachial plexus injury, 588 
and 962 CS should be performed for ultrasonographic estimated fetal weight of 
4500 and 4000 gm, respectively [83, 84]. So women with GDM and macrosomic 
fetus should be counseled about the elective CS risks and benefits [85].
6. Postpartum evaluation
Women with GDM should be evaluated postpartum as 15–70% will develop dia-
betes later in life [86–90]. These women were estimated to have sevenfold increased 
risk of developing type 2 DM when compared to controls [91]. So, screening after 
4–12 weeks of delivery is recommended to identify those with diabetes, impaired 
fasting glucose levels, or impaired glucose tolerance [11] (Figure 1).
ACOG practice bulletin No. 190: Gestational diabetes mellitus [4].
The Fifth International Workshop-Conference on Gestational Diabetes recom-
mended that women with GDM undergo evaluation with a 75-g oral glucose tolerance 
test at 6–12 weeks postpartum [92]. These recommendations are shown in Table 2.
Women with GDM are at an increased risk for cardiovascular complications 
associated with dyslipidemia, hypertension, and abdominal obesity—the metabolic 
syndrome [74].
Kessous and colleagues found that women with GDM were 2.6 times more likely 
to be hospitalized for cardiovascular morbidity [93].
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Shah and coworkers also reported excessive cardiovascular disease by 10 years in 
women with GDM [94].
7. Recurrent gestational diabetes
The risk of recurrence of GDM is estimated to be 40% in primiparous women [95]. 
Women with higher body mass index are more likely to have impaired glucose toler-
ance in subsequent pregnancies. Therefore, lifestyle modifications, including weight 
control and exercise between pregnancies, may prevent the recurrence of GDM [96]. 
Overweight and obese women in their first pregnancy will lower the risk of GDM, if 
they lose 2 or more units of their body mass index [97]. The risk of GDM in second 
pregnancy was 4.2% in women without GDM in their first pregnancy against 41.3 
percent in those with a history of gestational diabetes in their first pregnancy [98].
8. Contraception
Women with recent GDM can use low-dose hormonal contraceptives safely as 
the rate of developing of diabetes is similar in oral contraceptive users and nonusers 
Figure 1. 
Management of postpartum screening results. Abbreviations: FPG, fasting plasma glucose, OGTT, oral glucose 
tolerance test; IGT, impaired glucose tolerance.
Time Test Purpose
Post-delivery 1–3 days Fasting or random plasma 
glucose
Detect persistent, overt diabetes
Early postpartum 
(6–12 week)
75 g, 2-h OGTT Postpartum classification of glucose 
metabolism
1-year postpartum 75 g, 2-h OGTT Assess glucose metabolism
Annually Fasting plasma glucose Assess glucose metabolism
Triannually 75 g, 2-h OGTT Assess glucose metabolism
Prepregnancy 75 g, 2-h OGTT Classify glucose metabolism
Metzger et al. [92].
Table 2. 
Fifth international workshop-conference: Metabolic assessments recommended after pregnancy with gestational 
diabetes.
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of any hormonal contraception [99]. Care should be taken in women at risk of 
cardiovascular diseases as obese, hypertensive, and dyslipidemic women with direc-
tion of the contraceptive choice toward a method without potential cardiovascular 
consequences as intrauterine device.
Studies were reviewed and evaluated for quality according to the method 
outlined by the US Preventive Services Task Force:
I Evidence obtained from at least one properly designed randomized controlled 
trial.
II-1 Evidence obtained from well-designed controlled trials without 
randomization.
II-2 Evidence obtained from well-designed cohort or case–control analytic stud-
ies, preferably from more than one center or research group.
II-3 Evidence obtained from multiple time series with or without the interven-
tion. Dramatic results in uncontrolled experiments also could be regarded as this 
type of evidence.
III Opinions of respected authorities, based on clinical experience, descriptive 
studies, or reports of expert committees.
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